March 22, 2022
On March 4, 2022, BCN mailed a letter to one or more of your primary care physicians who have BCN AdvantageSM patients who are eligible for a new precision medicine pilot program using pharmacogenomic (PGx) testing. Attached is a generic copy of the letter and the fact sheet that went to physicians, along with a copy of the letter mailed to members selected for the pilot program.
If you’d like to learn more, you can view two online videos.
